Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.109

Nicoletta Colombo , Toon Van Gorp , Ursula Matulonis , Ana Oaknin , Rachel Grisham , Diane Provencher , Gini Fleming , Alexander Olawaiye , Hristina Pashova , Iulia Cristina Tudor , Lyndah Dreiling , Domenica Lorusso

引用次数: 0

查看原文本刊更多论文

选择性糖皮质激素受体调节剂 relacorilant 与纳布-紫杉醇联合治疗复发性铂类耐药卵巢癌患者的随机、开放标签 II 期研究的最终总生存期数据

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy